More Than 80% of Patients Respond to CAR T-Cell Therapy in Phase II NHL Trial – Targeted Oncology
Targeted Oncology |
More Than 80% of Patients Respond to CAR T-Cell Therapy in Phase II NHL Trial
Targeted Oncology More than 80% of patients with refractory non-Hodgkin lymphoma (NHL) achieved objective responses to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (KTE-C19), according to the results of a pivotal phase II trial.1 |
